Hydrogel Systems for Clinical Research emerging trends in Therapeutics

Authors

  • Mattaparthi Sri Sai Lakshmi Lasya Intern, Clinoxy Solutions Pvt.,Ltd., KPHB 9th Phase, Kukatpally, Back Side Nexus Mall (Forum Mall), NearJNTUH University, Hyderabad, Telangana.500085
  • Jana Lavanya Intern, Clinoxy Solutions Pvt.,Ltd., KPHB 9th Phase, Kukatpally, Back Side Nexus Mall (Forum Mall), NearJNTUH University, Hyderabad, Telangana.500085
  • Chandanaboina Jyoshna Intern, Clinoxy Solutions Pvt.,Ltd., KPHB 9th Phase, Kukatpally, Back Side Nexus Mall (Forum Mall), NearJNTUH University, Hyderabad, Telangana.500085
  • Satish Kumar Vemavarapu Founder, Clinoxy Solutions Pvt.,Ltd., KPHB 9th Phase, Kukatpally, Back Side Nexus Mall (Forum Mall), Near JNTUH University. Hyderabad. Telangana. 500085

Keywords:

Hydrogels, Injectable depot, Microneedles, Locoregional immunotherapy, Cell encapsulation, Clinical translation.

Abstract

This abstract summarizes current trends in hydrogel design and translational strategies that are advancing clinical research in therapeutics. It emphasizes responsive chemistries, device–drug combination pathways, and application niches with promising near-term clinical applications. Hydrogels are water-based polymer networks that can change their mechanical and transport properties. In the last ten years, they have quickly moved from research labs to real-world applications. Hydrogels are useful for several purposes: they can provide localized drug delivery, act as carriers for cells and genes, and serve as scaffolds for healing wounds and regenerating tissues. They are also effective in transdermal microneedle systems, which allow for painless drug administration. Hydrogels are becoming important platforms in clinical settings, effectively connecting biologics, small molecules, and cell therapies. They are particularly useful for local treatments, chronic wound repair, osteoarticular injections, and minimally invasive vaccine delivery. Early strategic engagement on chemistry, manufacturing, and controls (CMC) as well as regulatory pathways for combination products, along with the design of imaging-enabled endpoints, will help accelerate first-in-human studies and enhance the therapeutic impact.

Dimensions

Published

2025-10-17